@ ( @ % ) of @ patients given fingolimod @ mg and @ ( @ % ) of @ patients given placebo had serious adverse events over @ months , which included basal-cell carcinoma ( ten -LSB- @ % -RSB- patients vs two -LSB- @ % -RSB- patients ) , macular oedema ( three -LSB- @ % -RSB- vs two -LSB- @ % -RSB- ) , infections ( @ -LSB- @ % -RSB- vs four -LSB- @ % -RSB- ) , and neoplasms ( @ -LSB- @ % -RSB- vs eight -LSB- @ % -RSB- ) .